Related references
Note: Only part of the references are listed.A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
Xianbin Kong et al.
MOLECULAR MEDICINE REPORTS (2021)
Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review
Nathalia Alves Araujo de Almeida et al.
VIRUSES-BASEL (2021)
An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy
Zhenrui Shi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1
Kyoung-Ju Kim et al.
GENE THERAPY (2021)
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
Shinsuke Nakao et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Guan Wang et al.
NATURE COMMUNICATIONS (2020)
Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo
Syed Umar Faruq Syed Najmuddin et al.
CANCER CELL INTERNATIONAL (2020)
Cancer immune escape: MHC expression in primary tumours versus metastases
Federico Garrido et al.
IMMUNOLOGY (2019)
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
Giulia Marelli et al.
FRONTIERS IN IMMUNOLOGY (2018)
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
Chun-Yu Chen et al.
ONCOLYTIC VIROTHERAPY (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
Hong Jiang et al.
CANCER RESEARCH (2017)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice
Eric D. Thomas et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter et al.
ONCOIMMUNOLOGY (2016)
Programmed death-1 checkpoint blockade in acute myeloid leukemia
Alison Sehgal et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Oncolytic viruses get a boost with first FDA-approval recommendation
Elie Dolgin
NATURE REVIEWS DRUG DISCOVERY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Oncolytic viruses as therapeutic cancer vaccines
David L. Bartlett et al.
MOLECULAR CANCER (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Herpes simplex virus oncolytic vaccine therapy in melanoma
Shanthi Sivendran et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
